SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Nuvelo(NUVO) -- Ignore unavailable to you. Want to Upgrade?


To: nigel bates who wrote (114)12/11/2006 8:11:17 AM
From: idos  Read Replies (1) | Respond to of 140
 
Any idea what is the value of the rest of their pipe presuming Alfimeprase is dead?



To: nigel bates who wrote (114)12/11/2006 9:40:52 AM
From: DewDiligence_on_SI  Respond to of 140
 
Too bad for Ted Love, who seems like a nice guy. He was almost crying on the CC.

The “outcomes” endpoints used in phase-3 were much more challenging than the clot-lysing endpoints used in phase-2, but the real problem is that Alfimeprase has a very narrow therapeutic window.